Arrhythmias & electrophysiology
Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS
Authors' conclusion
The overall risk of death due to stroke or bleeding was low in XANTUS. Anticoagulated patients with AF remain at risk of death due to heart failure and sudden death.
Study context
- Population
- Patients with atrial fibrillation (AF) anticoagulated with rivaroxaban (XANTUS programme)
- Participants
- 11,040 patients
- Outcome
- Causes of death and factors associated with all-cause and CV death
- Follow-up
- Within a year after rivaroxaban initiation
Methodological detailscentral adjudication of causes of death
- Central adjudication of causes of death
Pooled result
As reported in the abstract
Death and causes of death
- Independent factors associated with all-cause or CV death: age, AF type, BMI, LVEF, hospitalization at baseline, rivaroxaban dose, anaemia
- Cause-of-death percentages are of the deaths (n = 187)
Further pooled results
Independent factors associated with all-cause or CV death
- Age, AF type, BMI, LVEF, hospitalization at baseline, rivaroxaban dose, anaemia
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS. Europace. Published 29 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →